- References (8)
Product nameAMD3100 octahydrochloride, CXCR4 antagonist
DescriptionHighly selective CXCR4 antagonist
- AMD 3100
- JM 3100
- SID 791
Plerixafor (hydrochloride) is a macrocyclic compound that acts as an irreversible antagonist against the binding of CXCR4 with its ligand, SDF-
It suppresses infection by HIV with an IC50 value of 1-
10 ng/ml with selectivity toward CXCR4- tropic virus. Plerixafor mobilizes hematopoietic stem and progenitor cells for transplant better than G- CSF alone. It also increases T- cell trafficking in the blood and spleen as well as the central nervous system. Plerixafor regulates the growth of primary and metastic breast cancer cells and inhibits dissemination of ovarian carcinoma cells.
Storage instructionsStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Soluble in PBS, pH 7.2, at 10 mg/ml.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
- Receptors & Transporters
- Enzyme-Linked Receptors
- Cytokine receptors
Uninfected control DCs were treated with MeAIB, MSO, inhibitors of CXCR4 (AMD3100), PI3K (LY294002) or Rho kinase (Y27632), or Gln starvation for 2 hours before assessing migration to 100 ng/ml SDF-1 α. Chemotactic index (CI) is defined as the fold increase in the number of migrating DCs to SDF-1 α over the spontaneous migration. One-way ANOVA reveals an effect of pharmacological treatments on the SDF-1 α-induced migration (F(6,44) = 6.700, P<0.001). Asterisks indicate P<0.05 (Dunnett's post hoc).
This product has been referenced in:
- De Clercq E The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 77:1655-64 (2009). Read more (PubMed: 19161986) »
- Rusconi S et al. New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses. Molecules 14:1927-37 (2009). Read more (PubMed: 19471212) »
- Fransen S et al. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition. Antimicrob Agents Chemother 52:2608-15 (2008). Read more (PubMed: 18443125) »
- Fricker SP et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 72:588-96 (2006). Read more (PubMed: 16815309) »
- Broxmeyer HE et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201:1307-18 (2005). Read more (PubMed: 15837815) »
- De Clercq E et al. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 38:668-74 (1994). Read more (PubMed: 7913308) »